In a move set to reshape the landscape of oral drug delivery, AustinPx—a Texas-based Contract Development and Manufacturing Organization (CDMO)—has entered into an exclusive, strategic agreement with Thermo Fisher Scientific’s Patheon division. This partnership centers on the integration of AustinPx’s proprietary KinetiSol technology into Patheon’s global manufacturing infrastructure, specifically at sites in Bend, Oregon, and Cincinnati, Ohio.
By embedding KinetiSol, a high-performance amorphous solid dispersion (ASD) platform, directly into the workflow of one of the world’s largest pharmaceutical service providers, the collaboration aims to provide drug developers with a seamless, scalable, and risk-mitigated pathway from early-stage discovery to commercial-scale manufacturing.
The Persistence of the Solubility Challenge
The pharmaceutical industry currently faces a daunting paradox: while our ability to identify potent drug targets has grown exponentially, the physical characteristics of the molecules themselves are becoming increasingly difficult to work with. According to data cited in a 2023 review in the journal Life, approximately 40% of all currently commercialized drugs suffer from poor solubility. More concerningly, that figure jumps to between 70% and 90% for candidates currently moving through the development pipeline.
Poor solubility is not merely a laboratory hurdle; it is a clinical bottleneck. When a drug is poorly soluble, its bioavailability—the proportion of the drug that enters the circulation and is able to have an active effect—is significantly compromised. This necessitates higher dosages, which in turn increases the risk of side effects, reduces patient compliance, and complicates the regulatory approval process.
For years, formulators have relied on traditional methods like spray drying and hot-melt extrusion (HME) to stabilize these molecules. However, these methods are not universal solutions. They often involve volatile solvents or high thermal exposure, which can degrade sensitive drug candidates. This is where the KinetiSol technology enters the conversation, offering a solvent-free, fusion-based process that opens doors for molecules previously deemed "undruggable" due to their physical constraints.
A Chronology of Collaboration and Technical Evolution
The integration of KinetiSol into the Patheon ecosystem is the result of years of refinement and strategic scaling.
- Early Innovation: AustinPx spent over 16 years perfecting the KinetiSol process, focusing on the fundamental physics of amorphous solid dispersions. Unlike HME, which relies on long residence times at high temperatures, KinetiSol utilizes high-shear, short-duration fusion to create stable dispersions.
- Proof of Concept: Over the past four years, AustinPx has successfully deployed the technology for more than 80 clients, proving that the technology is not just a laboratory curiosity but a robust, industrial-ready solution.
- The Partnership Formation: Recognizing the need for a global footprint to support late-stage clinical programs, AustinPx initiated discussions with Thermo Fisher Scientific. The resulting agreement, finalized in mid-2026, grants Thermo Fisher exclusive status as a third-party CDMO for the KinetiSol Formulator, ensuring that sponsors have a Tier-1 manufacturing partner available as their programs advance.
- Strategic Integration: The current phase involves the installation of KinetiSol equipment at key Patheon facilities, where it will be linked with the "Quadrant 2" platform—Thermo Fisher’s AI/ML-driven tool for predicting optimal formulation pathways.
The Role of Data: AI/ML and the Quadrant 2 Platform
One of the most significant aspects of this partnership is the synergy between physical manufacturing technology and digital predictive modeling. The "Quadrant 2" platform uses artificial intelligence and machine learning to predict how a molecule will behave in various formulation environments.
By feeding KinetiSol-specific process and formulation data into this platform, the accuracy of predictions is expected to climb. Elizabeth Hickman, CEO of AustinPx, notes that this integration helps developers avoid "low-value experiments." In the early stages of drug discovery, when API material is precious and limited, the ability to use an AI model to steer researchers toward the most viable technology—be it KinetiSol, spray drying, or HME—can shave months off development timelines and save millions in wasted R&D capital.
Official Perspective: Q&A with CEO Elizabeth Hickman
Q: Why choose an external CDMO partnership rather than building out your own massive manufacturing footprint?
Hickman: "Our core competency remains the invention and mastery of the KinetiSol process. While we have deep expertise, the pharmaceutical industry relies on massive, established networks like Thermo Fisher to move molecules from Phase 3 to the pharmacy shelf. By partnering with Patheon, we provide our clients with the confidence of scale. We are not just giving them a technology; we are giving them an ecosystem where that technology is already validated and supported by global logistics."
Q: What specific molecule types should favor KinetiSol over traditional methods?
Hickman: "The decision tree should be based on the molecule’s constraints. If a molecule has high melting points, is sensitive to long-term thermal exposure, or lacks solubility in the standard organic solvents required for spray drying, KinetiSol is often the superior choice. We are seeing a move away from the ‘one-size-fits-all’ approach. Scientists now realize that if you start with the wrong technology, you are essentially baking failure into your development cycle."
Q: Does the exclusivity of this agreement limit options for your clients?
Hickman: "On the contrary, it expands them. AustinPx remains the primary owner and expert of the technology. We continue to offer our internal services for those who need our specialized touch. By adding Thermo Fisher as a commercial-scale partner—alongside our existing partner, Microsize—we are providing a ‘defined route’ to commercialization. Sponsors no longer have to worry about a technology ‘dead-end’ when their drug hits the late-stage pipeline."
Implications for the Pharmaceutical Industry
The implications of this deal are twofold: the democratization of advanced formulation technology and the lowering of barriers to market entry for complex molecules.
1. Risk Mitigation for Sponsors
The primary barrier to adopting new technologies has historically been the fear of technology transfer. Sponsors worry that if they develop a drug using a niche technology, they will be unable to find a manufacturer capable of producing it at a global scale. By partnering with a giant like Thermo Fisher, AustinPx has effectively removed this "vendor risk." Sponsors can now initiate KinetiSol development knowing that the commercial manufacturing infrastructure is already waiting for them.
2. A Shift Toward "Formulation First"
The industry is moving toward a more sophisticated understanding of drug delivery. Instead of attempting to force a molecule into a conventional, off-the-shelf formulation, companies are now looking for technology that fits the molecule’s unique chemical signature. As this partnership matures, we can expect to see an increase in the number of "insoluble" molecules reaching the market, as developers feel more comfortable utilizing high-performance platforms earlier in the development lifecycle.
3. Sustainability and Efficiency
Beyond performance, KinetiSol offers a greener footprint. Because the process is solvent-free, it eliminates the environmental and safety risks associated with the massive volumes of organic solvents used in spray drying. As pharmaceutical companies face increasing pressure to improve their ESG (Environmental, Social, and Governance) scores, the adoption of inherently "greener" manufacturing technologies like KinetiSol is likely to accelerate.
Conclusion: A New Standard for CDMO Partnerships
The agreement between AustinPx and Thermo Fisher Scientific represents a shift toward a more collaborative, tech-forward era of drug manufacturing. By combining a boutique, high-performance technology with the logistical power of a global leader, the partnership addresses the most critical pain point in drug development: the bridge between a promising molecule and a viable, scalable, and patient-friendly product.
For the pharmaceutical industry, the message is clear: the era of struggling with poorly soluble drugs is being addressed not just by new chemistry, but by smarter, more integrated manufacturing strategies. As more programs adopt this collaborative model, the time required to bring life-saving medicines to market will continue to contract, ultimately benefiting the patients who rely on these innovations.
About the Author
